Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug

New Multiple Sclerosis drug, backed by 40 years of research, could halt disease
June 22, 2017
Bowel cancer ‘breakthrough’ at Queen’s University 
June 22, 2017
Show all

Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug

Comments are closed.